Cambridge Investment Research Advisors Inc. Has $2.13 Million Stock Position in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Cambridge Investment Research Advisors Inc. increased its position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL - Free Report) by 197.7% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 248,139 shares of the biotechnology company's stock after buying an additional 164,792 shares during the period. Cambridge Investment Research Advisors Inc. owned 0.29% of Anavex Life Sciences worth $2,129,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Northern Trust Corp grew its holdings in Anavex Life Sciences by 1.6% during the 4th quarter. Northern Trust Corp now owns 706,901 shares of the biotechnology company's stock worth $7,592,000 after acquiring an additional 10,938 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Anavex Life Sciences by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 677,215 shares of the biotechnology company's stock valued at $7,273,000 after purchasing an additional 11,239 shares in the last quarter. Invesco Ltd. grew its stake in Anavex Life Sciences by 2,419.8% during the fourth quarter. Invesco Ltd. now owns 615,048 shares of the biotechnology company's stock worth $6,606,000 after purchasing an additional 590,639 shares during the period. Pier Capital LLC bought a new stake in Anavex Life Sciences in the fourth quarter worth approximately $4,746,000. Finally, Essential Planning LLC. bought a new stake in Anavex Life Sciences in the fourth quarter worth approximately $4,437,000. Institutional investors and hedge funds own 31.55% of the company's stock.

Anavex Life Sciences Price Performance

Shares of AVXL traded up $0.15 during trading hours on Thursday, hitting $10.72. The stock had a trading volume of 800,367 shares, compared to its average volume of 1,189,449. Anavex Life Sciences Corp. has a 1-year low of $4.00 and a 1-year high of $14.44. The firm has a market capitalization of $915.17 million, a P/E ratio of -19.49 and a beta of 0.72. The firm has a 50 day simple moving average of $8.55 and a 200-day simple moving average of $9.11.

Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.16) by $0.03. During the same period last year, the firm posted ($0.13) earnings per share. Equities analysts predict that Anavex Life Sciences Corp. will post -0.69 EPS for the current fiscal year.

Wall Street Analyst Weigh In

AVXL has been the subject of several recent analyst reports. D. Boral Capital reaffirmed a "buy" rating and set a $46.00 price objective on shares of Anavex Life Sciences in a research report on Monday, April 7th. HC Wainwright reissued a "buy" rating and set a $42.00 target price on shares of Anavex Life Sciences in a research note on Monday, April 7th.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.